Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript

Core Insights - Tenax Therapeutics is developing TNX-103, an oral formulation of levosimendan, aimed at treating pulmonary hypertension with preserved ejection fraction (PH-HFpEF), which is currently in late-stage development with Phase III study data expected in the second half of 2026 [2] - The company emphasizes its unique mechanism of action and trial design, differentiating its approach from other investigational strategies in the PH-HFpEF space, which addresses a significant unmet medical need [3] Company Development - TNX-103 is positioned as a potential first-in-class treatment for PH-HFpEF, with a global Phase III study (LEVEL-2) set to initiate this year [2] - The company is focused on a different physiological target compared to other drugs in development, highlighting its innovative approach in the treatment landscape [3]